FTSE 100 news / Companies and sectors / GSK / 15 October 2026
GSK (GSK): news on Thursday 15 October 2026
+1.3 neutral
Coverage was split between GSK's $800 million Pennsylvania manufacturing investment, along with supportive analyst views and a share price rise, and reports of up to 1,217 job cuts in Belgium under its restructuring. The investment and analyst backing roughly offset the negative jobs headlines.
What drove it
- Pennsylvania $800M investment
- Belgium job cuts
- analyst ratings
The 34 stories
- +9.2 GSK to invest $800M in Pennsylvania, adding 300 jobs
$800M US investment and 300 jobs signals growth commitment - +9.2 Governor Shapiro Secures Over $800 Million Investment from GSK to Expand Operations, Creating Over 300 New Jobs and Growing Pennsylvania’s Robust Life Sciences Industry
Major $800M Pennsylvania investment announced - +8.3 GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion (GSK)
Strong Buy view on HIV and oncology growth - +8.3 GSK Pledges $800M to Scale Biologics Manufacturing at Pa. Facility
$800M biologics manufacturing scale-up - +8.3 Global Restructuring And US Biologics Bet Could Be A Game Changer For GSK (LSE:GSK)
Restructuring and US biologics bet framed as potential game changer - +7.5 GSK PLC (GSK) Shares Surge 3.5% -- What GF Score of 77 Tells Inv
Shares surged 3.5% with solid quality score - +7.5 GSK (LSE:GSK) Plans $800 Million Pennsylvania Expansion
Plans $800M Pennsylvania expansion - +7.5 Berenberg still a buyer of GSK, considering stock undervalued
Berenberg maintains buy, sees stock undervalued - +6.7 What Could GSK (LSE:GSK) Gain From Its $800 Million Pennsylvania Expansion?
Analysis of potential gains from Pennsylvania expansion - +6.7 FTSE 100 Climbs to 10,724.86, a Three-Week High, as AstraZeneca, GSK and Defence Stocks Lead
GSK among FTSE leaders as index hits three-week high - +6.7 GSK expanding operations in Montgomery County - Pennsylvania Business Report -
Operations expanding in Montgomery County - +5.8 GSK advances oncology pipeline with Mo-Rez phas...
Oncology pipeline progress with phase trial - +5.0 GSK and Oxford Uni begin IL-18 antibody study to map treatment effects in ulcerative colitis
New ulcerative colitis antibody study with Oxford - +5.0 GSK (LSE:GSK) Following Its ADS Filing And The Case For Undervaluation
Undervaluation case following ADS filing - +5.0 Why Is HUTCHMED (LSE:HCM) Stock In Focus After A Licensing Deal With FTSE 100 Drugmaker GSK And A US Filing?
Licensing deal with HUTCHMED involving GSK - −4.2 Pharmaceutical giant GSK to eliminate 1,200 jobs in Belgium
1,200 Belgian jobs to be eliminated - −4.2 GSK eyes over 1,200 Belgian job cuts in cost-saving drive
Over 1,200 Belgian job cuts, though cost-saving - −4.2 Shifts put more than 1,200 jobs at risk at GSK in Belgium
Shifts put over 1,200 Belgian jobs at risk - +4.2 RBC keeps target at GBp 1,975 for GSK stock ahead of results - ad-hoc-news.de
RBC keeps target ahead of results - −4.2 More than 1,200 jobs at risk at GSK in Belgium
More than 1,200 Belgian jobs at risk - −3.3 GSK plans to cut up to 1,217 jobs in Belgium as it begins three-year restructuring plan
Up to 1,217 Belgian job cuts in restructuring - −3.3 GSK planning 1,200 job cuts in Belgium, says paper
Report of 1,200 Belgian job cuts - −3.3 GSK to cut up to 1217 jobs in belgium as part of a restructuring
Up to 1,217 Belgian jobs cut in restructuring - −3.3 GSK could cut more than 1,200 jobs in Belgium
Could cut over 1,200 Belgian jobs - −3.3 GSK Plans 1,217 Job Cuts In Belgium
1,217 Belgian job cuts planned - −3.3 GSK plans to cut up to 1,217 jobs in Belgium - report
Report of up to 1,217 Belgian job cuts - −3.3 Market Chatter: GSK Plans Up to 1,217 Job Cuts in Belgium
Market chatter on Belgian job cuts - −3.3 GSK to cut up to 1,217 jobs in Belgium
Up to 1,217 Belgian job cuts - −3.3 GSK plans more than 1,200 job cuts in Belgium (GSK:NYSE)
Plans more than 1,200 Belgian job cuts - −3.3 GSK Plans to Cut Up to 1,217 Jobs in Belgium as Part of Restructuring
Up to 1,217 Belgian job cuts in restructuring - −2.5 GSK's cost-saving drive to see over 1200 jobs cut in Belgium
Cost-saving drive cuts over 1,200 Belgian jobs - −2.5 GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum
Belgian layoffs within $2.5B restructuring - −1.7 GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam
Layoffs as cost-saving programme gathers pace - −1.7 GSK’s Cost-Cutting Plan Reaches Belgium
Cost-cutting plan reaches Belgium
GSK: every day · Pharma and healthcare on 15 October 2026 · FTSE 100 overview for the day